Comprehensive Cardiac Sequencing Panel

Test Information

This panel of 108 genes is intended for patients with a diagnosis or clinical suspicion of inherited cardiac disorders and is performed by Next Generation Sequencing (NGS).

This molecular test is useful to confirm the diagnosis and to identify the disease causing mutations within a family to allow for carrier testing and prenatal diagnosis.

Turnaround Time

8-10 weeks

CPT Code(s)





Clinical Information

The comprehensive panel consists of 108 genes that are associated with a variety of structural abnormalities, arrhythmias, and syndromic presentations. Cardiomyopathies often present later in life and may be genetic or related to lifestyle factors or other health issues. Signs and symptoms of dilated cardiomyopathy may include congestive heart failure, fatigue, and shortness of breath. Arrhythmias are also common, and thrombotic events are more prevalent. Individuals with hypertrophic cardiomyopathy may be asymptomatic or exhibit with a wide range of severity, even within the same family. Common features include shortness of breath and chest pain, and these findings can occur at younger ages than dilated forms.

These disorders can be inherited as autosomal recessive, autosomal dominant, X-linked recessive, or X-linked dominant conditions. However, the inheritance pattern for some of these conditions is uncertain, and many of them exhibit incomplete penetrance.

In addition to the comprehensive panel, four subpanels can also be requested for Brugada syndrome (18 genes), Dilated & Arrhythmogenic cardiomyopathies (51 genes), hypertrophic cardiomyopathy (24 genes), and Long QT syndrome (18 genes).


Next Generation Sequencing


The current design of this panel covers all genes and the flanking intronic sequences. This method allows for analysis of greater than 98% of the targeted sequence for the detection of nucleotide substitutions and small deletions and duplications. Large deletions and duplications will not be detected by this panel. Mutations and variants identified on the panel are confirmed with Sanger sequencing. All novel and apparently pathogenic changes are reported when found within the coding region as well as within 10 basepairs of each intron/exon boundary for each gene. Promoter and 3' untranslated sequences are not included in the current analysis. It should be noted that the current protocol is not specifically designed to detect copy number alterations and single exon deletions may require additional follow-up to determine whether or not they represent technical artifacts.

We recommend further array-based testing to more accurately address the concerns of dosage alterations. The Cytogenetic Laboratory at GGC offers a high resolution microarray to complement the sequencing panel. The GGC Diagnostic Laboratory Directors are available for further consultation regarding the limitations of the NGS and array testing procedures.

Specimen Requirements

The preferred sample type is peripheral blood collected in an EDTA (purple top) tube – at least 2-3ml for pediatric patients and 5-6ml for adult patients. Extracted DNA and saliva are also accepted for this test.

Transport Instructions

The specimen should be kept at room temperature and delivered via overnight shipping. If shipment is delayed by one or two days, the specimen should be refrigerated and shipped at room temperature. Do not freeze the specimen. Samples collected on Friday can be safely designated for Monday delivery.

Prenatal Testing Information

If the pathogenic mutation(s) are identified in an affected individual using this panel, prenatal diagnosis is available for future pregnancies. Sanger sequencing will be used for prenatal diagnosis when there is a known familial mutation. Additional fees for cell culture and maternal cell contamination may apply. Maternal cell contamination studies are required for all prenatal molecular tests. Contact the laboratory prior to sending a prenatal specimen.

Have Questions? Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Kellie Walden, MS, CGC

Molecular Testing, NGS Panel, NGS Panels
Meet Ella

Meet Ella

We will remember February 26th for the rest of our lives. On that day, we received the call from the Greenwood Genetic Center that they had discovered our daughter, Ella Marie, has Kleefstra syndrome. Very early on, my wife, Kelly, observed Ella being delayed in some of her milestones. Kelly monitored Ella’s progression and sought out testing in an effort to get Ella some assistance. Along the way, we were sent to GGC and met with Dr. Roger Stevenson ...

In The News